Akcionáři společnosti Integer schválili převzetí společnosti Integer společností Armstrong Parent; pro fúzi hlasovalo 99,95 % odevzdaných hlasů. Dokončení transakce se po získání regulačních schválení očekává do konce roku 2026.
PLANO, Texas, Oct. 21, 2026 (GLOBE NEWSWIRE) -- Integer Holdings Corporation (NYSE: ITGR) (“Integer” or the “Company”) and Armstrong Parent, Inc. (“Parent”) today announced that, in connection with Parent’s proposed acquisition of the Company (the “Transaction”) contemplated by their Agreement and Plan of Merger, dated as of August 2, 2026 (the “Merger Agreement”), the stockholders of the Company have voted in favor of (1) the proposal to adopt the Merger Agreement and the Merger (the “First Proposal”) and (2) the proposal to approve, on an advisory (non-binding) basis, the compensation that will or may be paid or become payable to Integer’s named executive officers that is based on or otherwise related to the Transaction as contemplated in the Merger Agreement (the “Second Proposal”) at a special meeting of stockholders held on October 21, 2026 (the “Special Meeting”).
At the Special Meeting, (1) approximately 99.95% of the shares voted on the First Proposal were cast in favor of the First Proposal, representing approximately 76.66% of the total outstanding shares of Integer common stock as of the record date, September 8, 2026 (the “Record Date”), and (2) the Second Proposal was approved by a majority of the votes cast at the Special Meeting. The Company will provide a full report of the voting results from the Special Meeting in a Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission (the “SEC”).
The Transaction is anticipated to close by the end of 2026, subject to the satisfaction or waiver of customary closing conditions specified in the Merger Agreement, including the receipt of required regulatory approvals.
About Integer®
Integer Holdings Corporation (NYSE: ITGR) is one of the largest medical device contract development and manufacturing organizations (CDMOs) in the world, serving the cardio and vascular, neuromodulation, and cardiac rhythm management markets. As a strategic partner of choice, we advance the goals of our medical device customers through industry-leading engineering and manufacturing, with a relentless commitment to quality, service, and innovation. The Company’s brands include Greatbatch Medical® and Lake Region Medical®. Additional information is available at www.integer.net.
Contacts
Integer
Media Relations:
Misty Tippen [email protected]
469-536-6702
Some of the statements contained in this communication and other written and oral statements made from time to time by us and our representatives are not statements of historical or current fact. As such, they are “forward-looking statements” within the meaning of Section 27A of the Securities Act, and Section 21E of the Exchange Act, and are subject to the safe harbor created thereby under the Private Securities Litigation Reform Act of 1995. We have based these forward-looking statements on our current expectations, and these statements are subject to known and unknown risks, uncertainties and assumptions. Forward-looking statements include, but are not limited to, statements relating to: the completion of the Transaction on anticipated terms and timing, or at all, including obtaining regulatory approvals and satisfying other conditions to the completion of the Transaction; potential litigation relating to the Transaction that could be instituted against the parties to the Merger Agreement or their respective directors, managers, or officers, including the effects of any outcomes related thereto; our goals, plans, and strategic initiatives; long-term growth prospects; maximizing value for our stockholders; and other events, conditions or developments that will or may occur in the future; and timing of any of the foregoing. You can identify forward-looking statements by terminology such as “may,” “will,” “should,” “could,” “expects,” “intends,” “plans,” “anticipates,” “believes,” “estimates,” “predicts,” “projects,” “forecast,” “outlook,” “assume,” “potential” or “continue” or variations or the negative counterparts of these terms or other comparable terminology. These statements are only predictions and are no guarantee of future performance, and investors should not place undue reliance on forward-looking statements as predictive of future results. Actual events or results may differ materially from those stated or implied by these forward-looking statements. In evaluating these statements and our prospects, you should carefully consider the factors set forth below. All forward-looking statements attributable to us or persons acting on our behalf are expressly qualified in their entirety by these cautionary factors and to others contained throughout this communication.
Forward-looking statements by their nature address matters that are, to different degrees, uncertain, such as statements regarding the transactions contemplated by the Transaction. All such forward-looking statements are based upon current plans, estimates, expectations, opportunities and ambitions that are subject to risks, uncertainties, assumptions, and other important factors, many of which are beyond the control of the Company, that could cause actual results to differ materially from those expressed in such forward-looking statements. Key factors that could cause actual results to differ materially include, but are not limited to, the expected timing and likelihood of completion of the Transaction, including the timing, receipt and terms and conditions of any required governmental and regulatory approvals; the occurrence of any event, change or other circumstances that could give rise to the termination of the Transaction; the risk that the parties may not be able to satisfy the conditions to the Transaction in a timely manner or at all; risks related to disruption of management time from ongoing business operations due to the Transaction; the risk that any announcements relating to the Transaction could have adverse effects on the market price of the Company’s common stock; the risk that the Transaction and its announcement could have an adverse effect on the parties’ business relationships and business generally, including the ability of the Company to retain customers and retain and hire key personnel and maintain relationships with their suppliers and customers, and on their operating results and businesses generally; the risk of unforeseen or unknown liabilities; customer, regulatory and other stakeholder approvals and support; the risk of unexpected future capital expenditures; the risk of potential litigation relating to the Transaction that could be instituted against the Company or its directors and/or officers; the risk associated with third-party contracts containing material consent, anti-assignment, transfer or other provisions that may be related to the Transaction which are not waived or otherwise satisfactorily resolved; significant costs, or expenses incurred in connection with the Transaction; Parent’s ability to obtain the necessary financing arrangements set forth in the commitment letters received in connection with the Transaction; certain restrictions contained in the Merger Agreement that may impact the Company’s ability to pursue certain business opportunities or strategic transactions; the risk of various events that could disrupt operations, including pandemics, epidemics or other public health crises or severe weather (such as droughts, floods, avalanches and earthquakes), cybersecurity attacks, security threats and governmental response to them, and technological changes; the risks of labor disputes, changes in labor costs and labor difficulties; and the risks resulting from other effects of industry, market, economic, legal or legislative, political or regulatory conditions outside of the Company’s control. All such factors are difficult to predict and are beyond our control, including those detailed in the Company’s annual report on Form 10-K for the fiscal year ended December 31, 2025, which was filed with the SEC on February 23, 2026, the Company’s quarterly report on Form 10-Q for the fiscal quarter ended July 3, 2026, which was filed with the SEC on August 4, 2026 and other documents subsequently filed by the Company with the SEC. The Company’s forward-looking statements are based on assumptions that the Company believes to be reasonable but that may not prove to be accurate. Other unpredictable factors not discussed in this communication could also have material adverse effects on forward-looking statements. The Company does not assume an obligation to update any forward-looking statements, except as required by applicable law. These forward-looking statements speak only as of the date hereof.
Integer (ITGR) má 22. října 2026 před otevřením trhu zveřejnit výsledky za 3. čtvrtletí; analytici očekávají zisk 1,68 USD na akcii a tržby ve výši 456,91 milionu USD.
Integer (NYSE:ITGR – Get Free Report) is anticipated to announce its Q3 2026 results before the market opens on Thursday, October 22nd. Analysts expect the company to post earnings of $1.68 per share and revenue of $456.91 million for the quarter. Individuals can find conference call details on the company’s upcoming Q3 2026 earnings results page for the latest details on the call scheduled for Thursday, October 22, 2026 at 9:00 AM ET.
Integer (NYSE:ITGR – Get Free Report) last released its quarterly earnings results on Monday, August 3rd. The medical equipment provider reported $1.60 earnings per share for the quarter, beating the consensus estimate of $1.38 by $0.22. Integer had a return on equity of 12.79% and a net margin of 6.97%. The business had revenue of $464.11 million during the quarter, compared to analysts’ expectations of $451.07 million. During the same quarter last year, the business posted $1.55 EPS. The firm’s revenue for the quarter was down 2.6% compared to the same quarter last year. On average, analysts expect Integer to post $6.09 EPS for the current fiscal year and $6.71 EPS for the next fiscal year.
Integer Stock Performance NYSE:ITGR opened at $126.63 on Thursday. The company has a debt-to-equity ratio of 0.75, a current ratio of 3.73 and a quick ratio of 2.41. Integer has a 1 year low of $62.00 and a 1 year high of $126.79. The stock’s 50 day simple moving average is $125.91 and its two-hundred day simple moving average is $103.99. The company has a market cap of $4.31 billion, a price-to-earnings ratio of 34.60, a PEG ratio of 2.41 and a beta of 0.58.
Wall Street Analyst Weigh In A number of research analysts have recently commented on the company. Piper Sandler downgraded Integer from an “overweight” rating to a “hold” rating and set a $127.00 target price for the company. in a research report on Monday, August 3rd. Oppenheimer cut shares of Integer from an “outperform” rating to a “market perform” rating in a research report on Monday, August 3rd. Wells Fargo & Company upped their price target on shares of Integer from $84.00 to $127.00 and gave the company an “equal weight” rating in a research note on Tuesday, August 4th. HC Wainwright reiterated a “buy” rating on shares of Integer in a research report on Friday, July 24th. Finally, KeyCorp cut shares of Integer from an “overweight” rating to a “sector weight” rating in a research note on Monday, August 3rd. One equities research analyst has rated the stock with a Buy rating and thirteen have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and an average price target of $109.86. Check Out Our Latest Analysis on ITGR
Insider Activity at Integer In related news, insider Andrew Senn sold 9,408 shares of the stock in a transaction on Tuesday, September 8th. The stock was sold at an average price of $126.30, for a total transaction of $1,188,230.40. Following the sale, the insider owned 5,405 shares in the company, valued at approximately $682,651.50. This represents a 63.51% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, insider Kirk Thor sold 19,773 shares of the stock in a transaction on Monday, September 14th. The shares were sold at an average price of $126.25, for a total value of $2,496,341.25. Following the sale, the insider owned 18,920 shares in the company, valued at $2,388,650. The trade was a 51.10% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last three months, insiders have sold 40,948 shares of company stock worth $5,169,920. Corporate insiders own 1.10% of the company’s stock.
Integer Company Profile (Get Free Report)
Integer Holdings Corporation (NYSE: ITGR) is a medical device contract development and manufacturing company. The company designs, develops and manufactures components and finished products for medical device manufacturers, helping customers bring products from concept and development through commercial production.
Integer’s products and technologies support a range of medical applications, including cardiac and vascular devices, neuromodulation systems, orthopedics, and other specialty medical products.
Read More Five stocks we like better than Integer Tesla Wants to Make Its Own Chips—What Could Go Wrong? IREN Limited’s AI Pivot Gains Traction—But Can Its Data Centers Deliver? PBF Energy’s Stunning Rally Faces a Critical Test Citi Stock Falls Despite Earnings Beat: What Investors Need to Know
Receive News & Ratings for Integer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Integer and related companies with MarketBeat.com's FREE daily email newsletter.
Integer Holdings oznámila, že její seniorní konvertibilní dluhopisy s kupónem 2,125 % splňují podmínky ke konverzi od 1. října do 31. prosince 2026. Konverzní cena je přibližně 87,20 USD za akcii.
PLANO, Texas, Oct. 02, 2026 (GLOBE NEWSWIRE) -- Integer Holdings Corporation (NYSE: ITGR) (“Integer” or the “Company”), a leading medical device contract development and manufacturing organization, today notified holders of its 2.125% Convertible Senior Notes due 2028 (the “Notes”) that the Notes are convertible, at the option of the holders (the “Conversion Option”) beginning on October 1, 2026, and ending at the close of business on December 31, 2026. The Notes are convertible into cash, up to the principal amount of the Notes, and in cash, shares of the Company’s common stock or a combination thereof, at the Company’s election, in respect of the remainder, if any, of the Company’s conversion obligation in excess of the aggregate principal amount of the Notes being converted. Any determination regarding the convertibility of the Notes during future periods will be made in accordance with the terms of the Indenture governing the Notes.
The Notes became convertible because the last reported sale price of shares of the Company’s common stock, for at least 20 trading days (whether or not consecutive) during the period of 30 consecutive trading days ending on, and including, the last trading day of the calendar quarter ended September 30, 2026, was greater than 130% of the conversion price in effect on each applicable trading day.
The Notes are convertible at a conversion rate of 11.4681 shares of common stock per $1,000 principal amount of Notes, which is equivalent to a conversion price of approximately $87.20 per share of common stock.
The Company has issued a notice to holders with respect to the Conversion Option specifying the applicable terms, conditions and procedures. The notice is available through The Depository Trust Company or by requesting a copy from Wilmington Trust, National Association, which is serving as the conversion agent, at:
Wilmington Trust, National Association
1310 Silas Deane Highway
Wethersfield, CT 06109
Attn: Integer Holdings Corporation Notes Administrator
None of the Company, its Board of Directors or its employees has made or is making any representation or recommendation to any holder as to whether to exercise or refrain from exercising the Conversion Option.
This press release is not an offer to sell, nor a solicitation of an offer to buy securities, nor shall there be any sale of these securities in any state or jurisdiction in which the offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such state or jurisdiction.
About Integer®
Integer Holdings Corporation (NYSE: ITGR) is one of the largest medical device contract development and manufacturing organizations (CDMOs) in the world, serving the cardio and vascular, neuromodulation, and cardiac rhythm management markets. As a strategic partner of choice, we advance the goals of our medical device customers through industry-leading engineering and manufacturing, with a relentless commitment to quality, service, and innovation. The company's brands include Greatbatch Medical® and Lake Region Medical®. Additional information is available at www.integer.net.
Integer Holdings souhlasila s převzetím afiliacemi KKR za 127 USD za akcii v hotovosti, pokud budou splněny podmínky uzavření. Ve 2. čtvrtletí tržby klesly o 2,6 % na 464,1 mil. USD a upravené EPS vzrostlo o 3,2 %.
Key Takeaways Integer Holdings agreed to a $127-per-share cash acquisition by KKR affiliates, subject to closing conditions.ITGR's Q2 sales fell 2.6% to $464.1M, while adjusted EPS rose 3.2% despite softer revenues.ITGR faces weak adoption of three new products, while lower volumes pressured gross margin to 24.3%. Integer Holdings Corporation (ITGR - Free Report) has been gaining from its research and product development activities. The optimism, led by a mixed second-quarter 2026 performance and its strength in core product franchises, is expected to contribute further. However, new-product adoption concerns still persist.
This Zacks Rank #3 (Hold) company’s shares have gained 61.1% in the year-to-date against the industry’s 5% decline and the S&P 500’s 12.7% rise.
The renowned medical device outsourcing manufacturer has a market capitalization of $4.3 billion. The company projects 8.6% growth for the next five years and expects to maintain its strong performance going forward. Integer Holdings’ earnings surpassed the Zacks Consensus Estimate in the last reported quarter, delivering a trailing four-quarter average surprise of 6.3%.
Image Source: Zacks Investment Research
Factors Favoring Integer Holdings’ GrowthDefined Acquisition Consideration Creates a Clear Transaction Catalyst: On Aug. 2, 2026, Integer Holdings entered into a definitive agreement to be acquired by affiliates of Kohlberg Kravis Roberts & Co. L.P. (“KKR”). Under the transaction, each eligible share would be converted into the right to receive $127 in cash at closing. The acquisition is not subject to a financing condition, and the buyer has obtained equity and debt financing commitments. Completion remains subject to customary conditions, including approval by holders of a majority of outstanding shares and required regulatory clearances.
The agreement also provides for a $307 million parent termination fee in certain circumstances involving a buyer breach or failure to complete the transaction when required. If completed, Integer Holdings would become a wholly owned subsidiary of the buyer and its shares would be delisted from the NYSE. The pending acquisition therefore provides a defined cash value for shareholders, although realization depends on successful closing.
Core Product Franchises Retain Underlying Demand: Integer Holdings’ second-quarter 2026 performance indicates that weakness remains concentrated in a few new product programs rather than broad-based across its portfolio. C&V sales fell 2% year over year to $280.3 million, primarily due to lower-than-expected adoption of two new electrophysiology products. However, first-half C&V sales declined only 1% to $542 million, with foreign exchange and acquisitions providing modest support. CRM&N remained more resilient, with sales rising 1% to $173.7 million in the quarter and 3% to $342 million in the first half, despite softness in one neuromodulation product.
The broader sales picture also reflects the impact of the planned exit from Portable Medical, which drove a 43% decline in Other Markets sales in the second quarter and a 45% decline in the first half. Integer Holdings’ 2026 outlook continues to point to lower-than-anticipated adoption of three new products as the key drag on growth, with these programs previously expected to reduce organic sales growth by roughly 3% to 4%. This suggests that the company’s established portfolio remains relatively supportive, although improving execution and market adoption of the newer offerings will be important to offset the near-term pressure.
Mixed Q2 Results: Integer Holdings exited the second quarter of 2026 with a mixed performance. Revenues declined year over year, reflecting continued pressure from previously communicated product-related headwinds and the strategic exit from Portable Medical. However, adjusted earnings per share (EPS) increased 3.2%, supported by a relatively stable adjusted net income despite the softer top line.
On the product-line front, performance remained uneven. Cardio & Vascular sales declined as two new Electrophysiology products continued to weigh on results, while Cardiac Rhythm Management & Neuromodulation posted modest growth despite the impact from one new Neuromodulation product.
Factor That May Offset ITGR’s GainsNew-product adoption and EP forecast resets: Integer Holdings continues to face lower-than-anticipated market adoption for three recently launched products, including two in electrophysiology and one in neuromodulation. Second-quarter 2026 sales declined 2.6% year over year to $464.1 million. C&V sales were down 2% in the quarter, and the latest earnings release again identified the three products as a primary factor affecting 2026 sales. Lower production volumes also reduced fixed-cost absorption, contributing to a gross-margin decline to 24.3% from 27.1% a year earlier. The persistence of the issue raises execution risk until adoption improves.
Estimate TrendInteger Holdings is witnessing a stable estimate revision trend for 2026. In the past 30 days, the Zacks Consensus Estimate for earnings has remained stable at $6.09 per share.
The Zacks Consensus Estimate for the company’s third-quarter 2026 revenues is pegged at $457.3 million, indicating a 2.2% decline from the year-ago quarter’s reported number. The consensus mark for third-quarter earnings is pegged at $1.65 per share, implying a 7.8% decline from the year-earlier level.
Stocks to ConsiderSome better-ranked stocks from the broader medical space are Globus Medical (GMED - Free Report) , Veracyte (VCYT - Free Report) and West Pharmaceutical (WST - Free Report) .
Globus Medical, currently carrying a Zacks Rank #1 (Strong Buy), reported a second-quarter 2026 adjusted EPS of $1.34, which surpassed the Zacks Consensus Estimate by 19.6%. Revenues of $789.6 million beat the Zacks Consensus Estimate by 0.4%. You can see the complete list of today’s Zacks #1 Rank stocks here.
GMED has an estimated long-term earnings growth rate of 12.4%. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 27.9%.
Veracyte, currently flaunting a Zacks Rank #1, reported a second-quarter 2026 adjusted EPS of 54 cents, which surpassed the Zacks Consensus Estimate by 25.6%. Revenues of $150.3 million beat the Zacks Consensus Estimate by 4.1%.
VCYT has an estimated earnings growth rate of 8.4% for 2026. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 41.8%.
West Pharmaceutical, carrying a Zacks Rank #2 (Buy) at present, reported second-quarter 2026 adjusted EPS of $2.37, which beat the Zacks Consensus Estimate by 13.9%. Revenues of $872.3 million surpassed the Zacks Consensus Estimate by 4.2%.
WST has an estimated long-term earnings growth rate of 16%. WST’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 17.4%.
LOS ANGELES, Sept. 09, 2026 (GLOBE NEWSWIRE) -- Schall, Brown & Schwartz LLP (“SBS”), a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors in Integer Holdings Corporation (“Integer” or “the Company”) (NYSE: ITGR) for potential breaches of fiduciary duty on the part of its directors and management.
INVESTIGATION DETAILS: The investigation focuses on determining if the Integer board breached its fiduciary duties to shareholders. The Company announced on August 3, 2026, that it would be acquired by KKR at a price of $127 per share.
If you are a shareholder who suffered a loss, click here to participate.
We also encourage you to contact Brian Schall or David Schwartz of Schall, Brown & Schwartz LLP, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at www.schallfirm.com, or by email at [email protected]
WHY SBS? Schall, Brown & Schwartz LLP represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation. Bringing together the extensive experience and diverse skillsets of founding partners Brian Schall, Andrew Brown, and David Schwartz, SBS is dedicated to aggressively advocating for every investor.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.
CONTACT:
Schall, Brown & Schwartz LLP
Brian Schall, Esq.,
Andrew Brown, Esq.,
David Schwartz, Esq.,
www.schallfirm.com
Office: 310-301-3335 [email protected]
Integer Holdings čelí vyšetřování kvůli možnému porušení fiduciárních povinností vedením a představenstvem. Firma oznámila převzetí ze strany KKR za 127 USD za akcii.
Schall, Brown & Schwartz LLP (“SBS”), a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Integer Holdings Corporation (“Integer” or “the Company”) (NYSE: ITGR) for potential breaches of fiduciary duty on the part of its directors and management.
INVESTIGATION DETAILS: The investigation focuses on determining if the Integer board breached its fiduciary duties to shareholders. The Company announced on August 3, 2026, that it would be acquired by KKR at a price of $127 per share.
If you are a shareholder who suffered a loss, click here to participate.
We also encourage you to contact Brian Schall or David Schwartz of Schall, Brown & Schwartz LLP, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at www.schallfirm.com, or by email at [email protected]
WHY SBS? Schall, Brown & Schwartz LLP represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation. Bringing together the extensive experience and diverse skillsets of founding partners Brian Schall, Andrew Brown, and David Schwartz, SBS is dedicated to aggressively advocating for every investor.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.
View source version on businesswire.com: https://www.businesswire.com/news/home/20260823711418/en/
Integer Holdings ve 2. čtvrtletí zvýšil upravený zisk na akcii (EPS) na 1,60 USD, ale tržby klesly o 2,6 % na 464,1 mil. USD. Firma zároveň stáhla výhled po dohodě o prodeji KKR za 127 USD za akcii v hotovosti.
Key Takeaways Integer Holdings' Q2 adjusted EPS rose 3.2% to $1.60, while revenues fell 2.6% to $464.1M.C&V sales declined 2.3%, while CRM&N revenues rose 1% despite product-related headwinds.Integer Holdings withdrew its 2026 outlook after agreeing to KKR's $127-per-share cash acquisition. Integer Holdings Corporation (ITGR - Free Report) delivered adjusted earnings per share (EPS) of $1.60 in the second quarter of 2026, up 3.2% year over year. The figure beat the Zacks Consensus Estimate by 15.9%.
The adjustments include expenses related to the amortization of intangible assets and restructuring and restructuring-related charges, among others.
GAAP EPS for the quarter was 69 cents, down 33.7 % from the prior-year quarter.
ITGR’s Revenues in DetailInteger Holdings registered revenues of $464.1 million in the second quarter, down 2.6% year over year. However, the figure topped the Zacks Consensus Estimate by 2.2%.
Organically, revenues decreased 1.5%.
Integer Holdings’ Q1 Segmental AnalysisInteger Holdings operates through three product lines — Cardio and Vascular (C&V); Cardiac Rhythm Management & Neuromodulation (CRM&N) and Other Markets.
In the second quarter of 2026, the C&V product line generated revenues of $280.3 million, down 2.3% year over year. Organically, sales declined 2.5%. The decrease primarily reflected the previously communicated impact from two new Electrophysiology products.
The CRM&N product line reported revenues of $173.7 million, up 1% year over year. Organic sales also increased 1%. Growth in the product line was partially offset by the previously communicated impact from one new Neuromodulation product.
Revenues from Other Markets totaled $10.1 million, down 42.8% from $17.6 million in the prior-year quarter. Organically, sales declined 13.5%. The sharp reported decrease primarily reflected Integer Holdings’ strategic exit from the Portable Medical business.
ITGR’s Margin AnalysisInteger Holdings generated a gross profit of $112.9 million in the second quarter, down 12.6% year over year. The gross margin in the reported quarter contracted about 280 basis points (bps) to 24.3% from 27.1% in the prior-year period.
Selling, general and administrative expenses were $57.7 million, up 9% year over year. Research, development and engineering costs were $11.3 million in the quarter, down 20.8% year over year. Total operating expenses of $78.4 million increased 12.3% year over year.
Adjusted operating profit totaled $73 million, reflecting a decline of 10.2% from the prior-year quarter. Adjusted operating margin in the second quarter contracted about 130 bps to 15.7% from 17.1% a year ago.
Integer Holdings’ Financial PositionInteger Holdings exited the second quarter of 2026 with cash and cash equivalents of $21.4 million compared with $8.1 million at the first-quarter end. Total debt (including the current portion) at the end of second-quarter 2026 was $1.24 billion, down from $1.25 billion at the end of the first quarter.
Cumulative cash flow from operating activities at the end of second-quarter 2026 was $84.4 million compared with $75.1 million a year ago.
Integer Holdings’ KKR Deal Reshapes the OutlookInteger Holdings and KKR separately announced a definitive agreement under which an affiliate of KKR-managed investment funds will acquire all outstanding Integer shares for $127 per share in cash. The transaction carries an enterprise value of $5.7 billion.
Given the pending transaction, Integer Holdings withdrew its previously issued financial outlook. The company also canceled its previously scheduled second-quarter earnings conference call and webcast.
Wrapping UpInteger Holdings exited the second quarter of 2026 with a mixed performance. Revenues declined year over year, reflecting continued pressure from previously communicated product-related headwinds and the strategic exit from Portable Medical. However, adjusted EPS increased 3.2%, supported by a relatively stable adjusted net income despite the softer top line.
On the product-line front, performance remained uneven. Cardio & Vascular sales declined as two new Electrophysiology products continued to weigh on results, while Cardiac Rhythm Management & Neuromodulation posted modest growth despite the impact from one new Neuromodulation product. Profitability also remained under pressure, with adjusted operating income declining 10.2% and gross margin contracting year over year. Still, operating cash flow for the first six months improved to $84.4 million from $75.1 million a year ago.
The company withdrew its previously issued 2026 financial outlook in light of the pending acquisition. Integer Holdings and KKR announced a definitive agreement under which an affiliate of KKR-managed investment funds will acquire all outstanding shares of ITGR for $127 per share in cash, valuing the transaction at an enterprise value of $5.7 billion.The transaction is expected to close by the end of 2026.
Integer Holdings’ Zacks Rank & Key PicksInteger Holdings currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the broader medical space are McKesson (MCK - Free Report) , Phibro Animal Health (PAHC - Free Report) andCardinal Health (CAH - Free Report) .
McKesson carries a Zacks Rank #2 (Buy) at present and has an estimated long-term growth rate of 13.7%. MCK’s earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 3.09%. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
McKessonshares have gained 8.8% against the industry’s 12.7% decline in the year-to-date period.
Phibro Animal Health, carrying a Zacks Rank of 2 at present, has an estimated long-term growth rate of 21.5%. PAHC’s earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 16.25%.
Phibro Animal Health stock has climbed 44.2% against the industry’s 17.1% decline in the year-to-date period.
Cardinal Health, carrying a Zacks Rank of 2 at present, has an estimated long-term growth rate of 17%. CAH’s earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 10.27%.
Cardinal Health’s shares have lost 2.6% compared with the industry’s 3.1% decline in the year-to-date period.
Kahn Swick & Foti prověřuje plánovaný prodej Integer Holdings (NYSE: ITGR) společnosti KKR za 127,00 USD za akcii. Zkoumá, zda je tato cena a proces prodeje pro akcionáře spravedlivý.
NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Integer Holdings Corporation (NYSE: ITGR) to KKR. Under the terms of the proposed transaction, shareholders of Integer will receive $127.00 in cash for each share of Integer that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whether the consideration undervalues the Company.
If you believe that this transaction undervalues the Company and/or if you would like to discuss your legal rights regarding the proposed sale, you may, without obligation or cost to you, e-mail or call KSF Managing Partner Lewis S. Kahn ([email protected]) toll free at any time at (833) 538-3612, or visit https://www.ksfcounsel.com/cases/nyse-itgr/ to learn more.
To learn more about KSF, whose partners include the Former Louisiana Attorney General, visit www.ksfcounsel.com.
Integer (ITGR - Free Report) came out with quarterly earnings of $1.6 per share, beating the Zacks Consensus Estimate of $1.38 per share. This compares to earnings of $1.55 per share a year ago. These figures are adjusted for non-recurring items.
This quarterly report represents an earnings surprise of +15.94%. A quarter ago, it was expected that this medical device outsource manufacturer would post earnings of $1.21 per share when it actually produced earnings of $1.2, delivering a surprise of -0.83%.
Over the last four quarters, the company has surpassed consensus EPS estimates three times.
Integer, which belongs to the Zacks Medical - Instruments industry, posted revenues of $464.11 million for the quarter ended June 2026, surpassing the Zacks Consensus Estimate by 2.58%. This compares to year-ago revenues of $476.49 million. The company has topped consensus revenue estimates four times over the last four quarters.
The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.
Integer shares have added about 54.5% since the beginning of the year versus the S&P 500's gain of 9.4%.
What's Next for Integer?While Integer has outperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?
There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.
Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.
Ahead of this earnings release, the estimate revisions trend for Integer was mixed. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.
It will be interesting to see how estimates for the coming quarters and the current fiscal year change in the days ahead. The current consensus EPS estimate is $1.66 on $458.79 million in revenues for the coming quarter and $6.04 on $1.82 billion in revenues for the current fiscal year.
Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Medical - Instruments is currently in the bottom 38% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.
Another stock from the same industry, Sight Sciences, Inc. (SGHT - Free Report) , has yet to report results for the quarter ended June 2026. The results are expected to be released on August 5.
This company is expected to post quarterly loss of $0.15 per share in its upcoming report, which represents a year-over-year change of +34.8%. The consensus EPS estimate for the quarter has remained unchanged over the last 30 days.
Sight Sciences, Inc.'s revenues are expected to be $21.75 million, up 11.2% from the year-ago quarter.
~ Transaction to Advance Integer’s Innovation and Growth in Support of Customers and Patients ~
PLANO, Texas and NEW YORK, Aug. 03, 2026 (GLOBE NEWSWIRE) -- Integer Holdings Corporation (NYSE: ITGR) (“Integer” or the “Company”), a leading global medical device contract development and manufacturing organization (CDMO), and KKR, a leading global investment firm, today announced that they have entered into a definitive agreement under which an affiliate of investment funds managed by KKR will acquire all of the outstanding shares of Integer in an all-cash transaction valued at an enterprise value of approximately $5.7 billion.
Under the terms of the agreement, Integer stockholders will receive $127 per share, representing a premium of approximately 51.8% to Integer’s closing share price on April 29, 2026, the date prior to the Company’s announcement of a strategic review, and 28.8% to the 30-day VWAP as of July 31, 2026.
“This is an exciting milestone for Integer and a testament to the dedication and commitment of our talented team and the exceptional business we have built together,” said Payman Khales, Integer’s President and CEO. “We believe this transaction recognizes the strength of Integer’s business, which includes our dedicated associates, our differentiated engineering and manufacturing capabilities, and our long-term growth opportunities, while providing stockholders with immediate and certain value. KKR’s deep healthcare expertise, long-term vision, and strategic growth orientation make them the right strategic partner to bring our business into its next chapter. Together, we look forward to continuing to invest in our associates and capabilities to deliver excellence for our customers and advance our vision of improving patients’ lives.”
“Integer is an exceptional platform with highly differentiated capabilities across a global manufacturing footprint, a track record for quality and reliability, and a talented team operating in attractive, durable end-markets,” said Max Lin, Partner at KKR. “We are excited by the opportunity to deploy capital and resources to further advance Integer’s next chapter of growth and innovation. We look forward to partnering with the management team and the 11,000 associates to build on Integer’s position as a trusted strategic partner to leading medical device companies and emerging innovators, helping bring life-saving and life-enhancing technologies to patients around the globe.”
As a KKR portfolio company, Integer will have additional flexibility and long-term capital to invest in capacity, technology, innovation, and talent in support of its customers and the patients who rely on the products Integer helps bring to market. KKR intends to establish a broad-based employee ownership and engagement program at Integer following the close of the transaction, consistent with its longstanding approach of fostering an ownership culture and extending ownership to employees across its portfolio. Since 2011, KKR portfolio companies have awarded billions of dollars of total equity value to over 200,000 non-senior management employees across more than 90 companies.
Transaction Details
The definitive agreement follows the comprehensive strategic review announced by Integer on April 30, 2026. In consultation with management and its financial and legal advisors, the Integer Board considered a range of potential alternatives to ensure the Company is best positioned for continued success and to maximize stockholder value. The Board determined that the transaction with KKR represents the best path forward for Integer and delivers immediate and certain value to its stockholders.
The transaction is expected to close by the end of the year, subject to the satisfaction of customary closing conditions, including approval by Integer stockholders and the receipt of required regulatory approvals. The Integer Board has unanimously approved the agreement and recommends that Integer stockholders vote their shares to approve the transaction and adopt the merger agreement. This transaction is not subject to any financing contingency.
KKR will make its investment in Integer through its core private equity strategy and finance the transaction through a combination of equity provided by investment funds managed by KKR and committed debt financing.
Upon completion of the transaction, Integer will become a privately held company and Integer’s common stock will no longer be listed on the New York Stock Exchange.
Integer Second Quarter 2026 Results
In a separate press release issued today, Integer reported second quarter 2026 financial results. Given the pending transaction with KKR, Integer is withdrawing its previously issued financial outlook and will not host its earnings conference call and webcast that has been scheduled for Thursday, August 6, 2026.
That press release, along with other investor materials, including reconciliations of certain non-GAAP measures to their nearest GAAP measures, will be available on investor.integer.net.
Advisors
Goldman Sachs & Co. LLC is serving as Integer’s exclusive financial advisor and Davis Polk & Wardwell LLP is serving as legal advisor. Centerview Partners, Barclays, Citi, and Raymond James are serving as financial advisors to KKR. Kirkland & Ellis LLP is serving as legal advisor to KKR. Citi, KKR Capital Markets, Barclays, UBS and Jefferies will act as lead arrangers for the debt financing in connection with the transaction.
About Integer®
Integer Holdings Corporation (NYSE: ITGR) is one of the largest medical device contract development and manufacturing organizations (CDMOs) in the world, serving the cardio and vascular, neuromodulation, and cardiac rhythm management markets. As a strategic partner of choice, we advance the goals of our medical device customers through industry-leading engineering and manufacturing, with a relentless commitment to quality, service, and innovation. The company's brands include Greatbatch Medical® and Lake Region Medical®. Additional information is available at www.integer.net.
About KKR
KKR is a leading global investment firm that offers alternative asset management as well as capital markets and insurance solutions. KKR aims to generate attractive investment returns by following a patient and disciplined investment approach, employing world-class people, and supporting growth in its portfolio companies and communities. KKR sponsors investment funds that invest in private equity, credit and real assets and has strategic partners that manage hedge funds. KKR’s insurance subsidiaries offer retirement, life and reinsurance products under the management of Global Atlantic Financial Group. References to KKR’s investments may include the activities of its sponsored funds and insurance subsidiaries. For additional information about KKR & Co. Inc. (NYSE: KKR), please visit KKR’s website at www.kkr.com. For additional information about Global Atlantic Financial Group, please visit Global Atlantic Financial Group’s website at www.globalatlantic.com.
Contacts
Integer
Media Relations:
Misty Tippen [email protected]
469-536-6702
Cautionary Statement Regarding Forward-Looking Statements
Some of the statements contained in this communication and other written and oral statements made from time to time by us and our representatives are not statements of historical or current fact. As such, they are “forward-looking statements” within the meaning of Section 27A of the Securities Act, and Section 21E of the Exchange Act, and are subject to the safe harbor created thereby under the Private Securities Litigation Reform Act of 1995. We have based these forward-looking statements on our current expectations, and these statements are subject to known and unknown risks, uncertainties and assumptions. Forward-looking statements include, but are not limited to, statements relating to: our goals, plans, and strategic initiatives; long-term growth prospects; maximizing value for our stockholders; and other events, conditions or developments that will or may occur in the future; and timing of any of the foregoing. You can identify forward-looking statements by terminology such as “may,” “will,” “should,” “could,” “expects,” “intends,” “plans,” “anticipates,” “believes,” “estimates,” “predicts,” “projects,” “forecast,” “outlook,” “assume,” “potential” or “continue” or variations or the negative counterparts of these terms or other comparable terminology. These statements are only predictions and are no guarantee of future performance, and investors should not place undue reliance on forward-looking statements as predictive of future results. Actual events or results may differ materially from those stated or implied by these forward-looking statements. In evaluating these statements and our prospects, you should carefully consider the factors set forth below. All forward-looking statements attributable to us or persons acting on our behalf are expressly qualified in their entirety by these cautionary factors and to others contained throughout this communication.
Forward-looking statements by their nature address matters that are, to different degrees, uncertain, such as statements regarding the transactions contemplated by the Agreement and Plan of Merger, by and among the Company, Armstrong Parent, Inc. (“Buyer”) and Armstrong Bidco, Inc. (the “Transaction”). All such forward-looking statements are based upon current plans, estimates, expectations, opportunities and ambitions that are subject to risks, uncertainties, assumptions, and other important factors, many of which are beyond the control of the Company, that could cause actual results to differ materially from those expressed in such forward-looking statements. Key factors that could cause actual results to differ materially include, but are not limited to, the expected timing and likelihood of completion of the Transaction, including the timing, receipt and terms and conditions of any required governmental and regulatory approvals; the occurrence of any event, change or other circumstances that could give rise to the termination of the Transaction; the possibility that the Company’s stockholders may not approve the Transaction; the risk that the parties may not be able to satisfy the conditions to the Transaction in a timely manner or at all; risks related to disruption of management time from ongoing business operations due to the Transaction; the risk that any announcements relating to the Transaction could have adverse effects on the market price of the Company’s common stock; the risk that the Transaction and its announcement could have an adverse effect on the parties’ business relationships and business generally, including the ability of the Company to retain customers and retain and hire key personnel and maintain relationships with their suppliers and customers, and on their operating results and businesses generally; the risk of unforeseen or unknown liabilities; customer, stockholder, regulatory and other stakeholder approvals and support; the risk of unexpected future capital expenditures; the risk of potential litigation relating to the Transaction that could be instituted against the Company or its directors and/or officers; the risk associated with third-party contracts containing material consent, anti-assignment, transfer or other provisions that may be related to the Transaction which are not waived or otherwise satisfactorily resolved; significant costs, or expenses incurred in connection with the Transaction; the Buyer’s ability to obtain the necessary financing arrangements set forth in the commitment letters received in connection with the Transaction; certain restrictions contained in the Agreement and Plan of Merger that may impact the Company’s ability to pursue certain business opportunities or strategic transactions; the risk of various events that could disrupt operations, including pandemics, epidemics or other public health crises or severe weather (such as droughts, floods, avalanches and earthquakes), cybersecurity attacks, security threats and governmental response to them, and technological changes; the risks of labor disputes, changes in labor costs and labor difficulties; and the risks resulting from other effects of industry, market, economic, legal or legislative, political or regulatory conditions outside of the Company’s control. All such factors are difficult to predict and are beyond our control, including those detailed in the Company’s annual report on Form 10-K for the fiscal year ended December 31, 2025, which was filed with the Securities Exchange Commission (the “SEC”) on February 23, 2026 (the “Form 10-K”), quarterly reports on Form 10-Q and other documents subsequently filed by the Company with the SEC. The Company’s forward-looking statements are based on assumptions that the Company believes to be reasonable but that may not prove to be accurate. Other unpredictable or factors not discussed in this communication could also have material adverse effects on forward-looking statements. The Company does not assume an obligation to update any forward-looking statements, except as required by applicable law. These forward-looking statements speak only as of the date hereof.
Additional Information and Where to Find It
In connection with the Transaction, the Company will file with the SEC a proxy statement on Schedule 14A. The definitive proxy statement will be sent to the stockholders of the Company seeking their approval of the Transaction and other related matters.
BEFORE MAKING ANY INVESTMENT OR VOTING DECISION, INVESTORS AND SECURITY HOLDERS OF THE COMPANY ARE URGED TO READ THE PROXY STATEMENT ON SCHEDULE 14A WHEN IT BECOMES AVAILABLE, AS WELL AS ANY OTHER RELEVANT DOCUMENTS FILED OR THAT WILL BE FILED WITH THE SEC IN CONNECTION WITH THE TRANSACTION OR INCORPORATED BY REFERENCE INTO THE PROXY STATEMENT, BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION REGARDING THE COMPANY, THE TRANSACTION AND RELATED MATTERS.
Investors and security holders may obtain free copies of these documents, including the proxy statement, and other documents filed with the SEC by the Company through the website maintained by the SEC at https://www.sec.gov. Copies of documents filed with the SEC by the Company will be made available free of charge by accessing the Company’s website at https://investor.integer.net/financial-information/sec-filings/default.aspx or by contacting the Company via email by sending a message to [email protected].
Participants in the Solicitation
The Company, Buyer and their respective directors and executive officers may be deemed to be participants in the solicitation of proxies from the stockholders of the Company in connection with the Transaction under the rules of the SEC. Information about the directors and executive officers of the Company and other persons who may be deemed to be participants in the solicitation of stockholders of the Company in connection with the Transaction and a description of their direct and indirect interests, by security holdings or otherwise, will be included in the proxy statement and other relevant material related to the Transaction, which will be filed with the SEC when they become available, and may be found in the Company’s definitive proxy statement in connection with its 2026 Annual Meeting of Stockholders, as filed with the SEC on April 6, 2026 (the “2026 Proxy Statement”), and in the Form 10-K, and subsequently filed statements of beneficial ownership on Form 4. Information about the directors and executive officers of the Company, their ownership of the Company common stock, and the Company’s transactions with related persons is set forth in the sections entitled “Directors, Executive Officers and Corporate Governance,” “Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters,” and “Certain Relationships and Related Transactions, and Director Independence” included in the Form 10-K, and in the sections entitled “Corporate Governance and Board Matters,” and “Security Ownership of Certain Beneficial Owners and Management,” included in the 2026 Proxy Statement. Additional information regarding the interests of such participants in the solicitation of proxies in respect of the Transaction will be included in the proxy statement and other relevant materials to be filed with the SEC when they become available. These documents can be obtained free of charge from the SEC’s website at www.sec.gov.
No Offer or Solicitation
This communication is not intended to and shall not constitute an offer to sell or the solicitation of an offer to sell or the solicitation of an offer to buy any securities or the solicitation of any vote or approval, nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. No offer of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act.
